Rapidly increasing market demand drives executive team expansion at pioneering virtual clinical trials company
NEW YORK, September 21, 2018 (Newswire.com) - Transparency Life Sciences (TLS), the first all-digital drug development services company, today announced that Donna Thornton has joined the company as Vice President of Business Development. She will oversee all sales efforts for the company.
A 20-year veteran of the clinical services and technology industries, Thornton most recently led Oracle’s business development efforts for its platform of “software as a service” (SaaS) clinical trials applications. Her clinical trial expertise and insights into the transformative power of digital services in healthcare will help Transparency Life Sciences accelerate the industry’s transition to all-digital trials, with the goal of making trials more relevant to patients, more efficient for drug developers, and ultimately, speeding access to life-saving medicines.
“Growing our sales and marketing team has been one of our top priorities this year, and I am thrilled to welcome Donna to our team,” said Tomasz Sablinski, CEO Transparency Life Sciences. “Her extensive background in clinical services business development, understanding of customers’ needs, vision for digital health, and enthusiasm for an all-digital approach to clinical trials will be a powerful force to help accelerate our growth.”
Growing our sales and marketing team has been one of our top priorities this year, and I am thrilled to welcome Donna to our team. Her extensive background in clinical services business development, understanding of customers' needs, vision for digital health, and enthusiasm for an all-digital approach to clinical trials will be a powerful force to help accelerate our growth.
John Watson, a member of TLS’s Board of Directors and formerly Chief Commercial Officer of Covance, commented, “I’ve watched Donna’s development at Covance and Oracle, and am delighted to have her join the team at Transparency Life Sciences. Her dual expertise in clinical services and technology should greatly accelerate the company’s growth and reach.”
Thornton holds a Bachelor’s degree from Temple University and a MBA from Philadelphia University. She serves as an executive on the Board of Women Visitors for the University of Pennsylvania Health System and as Committee Representative for the Abramson Cancer Center, where she advocates for excellence in patient care.
About Transparency Life Sciences
Transparency Life Sciences (TLS) is the first all-digital drug development services company. TLS’s approach combines crowdsourcing and integrated mobile health technology to advance drug candidates through clinical trials with unprecedented efficiency and patient and regulatory relevance. The use of digital technology allows TLS to reduce or eliminate reliance on physical study sites that are expensive, complex and inconvenient for patients, and limit the geographic scope of enrollment. For more information, visit transparencyls.com.
Source: Transparency Life Sciences